Synthesis and immunostimulating properties of lipophilic ester and ether muramyl peptide derivatives

Journal of Medicinal Chemistry

Volumn 39, Issue 22, 1996, Pages 4483-4488

  Merhi, Ghada ^a   Coleman, Anthony W ^a   Devissaguet, Jean Philippe ^a   Barratt, Gillian M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL DERIVATIVE; IMMUNOSTIMULATING AGENT; MURAMYL DIPEPTIDE DERIVATIVE; MURAMYL TRIPEPTIDE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; IMMUNOSTIMULATION; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN;

ACETYLMURAMYL-ALANYL-ISOGLUTAMINE; ANIMALS; ENZYME INDUCTION; MACROPHAGE ACTIVATION; MICE; NITRIC OXIDE SYNTHASE;

EID: 0029956808     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960147u     Document Type: Article

References (30)

1. Adam, A.; Lederer, E. Muramylpeptides: immunomodulators, sleep factors and vitamins. Med. Res. Rev. 1984, 4, 111-152.
2. Barratt, G. M.; Yu, W.-P.; Fessi, H.; Devissaguet, J.-Ph.; Petit, J.-F.; Tenu, J.-P.; Israel, L.; Morère, J.-F.; Puisieux, F. Delivery of MDP-L-alanyl-cholesterol to macrophages: comparison of liposomes and nanocapsules. Cancer J. 1990, 2, 439-443.
3. Brace, N. O. Free radical addition of iodoperfluoroalkanes to terminal alkadienes. Relative reactivity as a function of chain length and reaction conditions. J. Org. Chem. 1973, 38, 3167-3172.
4. Daemen, T.; Dontje, B. H.; Veninga, A.; Scherphof, G. L.; Oosterhuis, W. L. Therapy of murine liver metastases by administration of MDP encapsulated in liposomes. Select. Cancer Ther. 1990, 6, 63-71.
5. Daemen, T.; Veninga, A.; Roerdink, F.; Scherphof, G. L. In vitro activation of rat liver macrophages to tumoricidal activity by free or liposome-encapsulated muramyl dipeptide. Cancer Res. 1986, 46, 4330-4335.
6. Daemen, T.; Veninga, A.; Dijkstra, J.; Scherphof, G. L. Differential effects of liposome-incorporation on liver macrophage activating properties of rough lipopolysaccharide, lipid A and muramyl dipeptide. Differences in susceptibility to lysosomal enzymes. J. Immunol. 1989, 142, 2469-2474.
7. Devissaguet, J.-P.; Fessi, H.; Puisieux, F. Process for the preparation of dispersible colloidal systems of a substance in the form of nanocapsules. U.S. Patent 5,049,322, 1991.
8. Drapier, J. C.; Hibbs, J. B. Differentiation of murine macrophages to express non specific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells. J. Immunol. 1988, 140, 2829-2838.
9. Fidler, I. J.; Kleinerman, E. S. Therapy of cancer metastasis by systemic activation of macrophages: from the bench to the clinic. Res. Immunol. 1993, 144, 284-287.
10. Fidler, I. J.; Sone, S.; Fogler, W. E.; Barnes, Z. L. Eradication of spontaneous metastases and activation of alveolar macrophages by intravenous injection of liposomes containing muramyldipeptide. Proc. Natl. Acad. Sci U.S.A. 1981, 78, 1680-1684.
11. 3H]nor-muramyl tripeptide phosphatidylethanolamine in mice. J. Immunol. 1985, 135, 1372-1377.
12. Freedman, H. H. An improved Williamson ether synthesis using phase transfer catalysis. Tetrahedron 1975, 38, 3251-3254.
13. 15N] nitrate in biological fluids. Anal. Biochem. 1982, 126, 131-138.
14. Kleinermann, E. S.; Erickson, K. L.; Schroit, A. J.; Fogler, W. E.; Fidler, I. J. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res. 1983, 43, 2010-2014.
15. Level, M. Thèse d'Etat de l'Université Paris, XI, 1987.
16. Mehta, K.; Lopez-Berestein, G.; Hersh, E. M.; Juliano, R. L. Uptake of liposomes and liposome-encapsulated muramyl dipeptide by human peripheral blood monocytes. J. Reticuloend. Soc. 1982, 32, 155-164.
17. Morin, C.; Barratt, G.; Fessi, H.; Devissaguet, J.-P.; Puisieux, F. Biodegradable nanocapsules containing a lipophilic immunomodulator: drug retention and tolerance towards macrophages in vitro. J. Drug Targeting 1993, 1, 157-164.
18. Morin, C.; Barratt, G.; Fessi, H.; Devissaguet, J.-P.; Puisieux, F. Improved intracellular delivery of a muramyldipeptide analog by means of nanocapsules. Int. J. Immunopharmacol. 1994, 16, 451-456.
19. Neumann, W. P. Tri-n-butyltin hydride as reagent in organic synthesis. Synthesis 1987, No. 8, 665-683.
20. 14C-labelled) in the mouse. Int. J. Immunopharmacol. 1979, 1, 35-41.
21. Phillips, N. C.; Moras, M. L.; Chedid, L.; Petit, J. F.; Tenu, J. P.; Lederer, E.; Bernard, J. M.; Lefrancier, P. Activation of macrophage cytostatic and cytotoxic activity in-vitro by liposomes containing a new lipophilic muramyl dipeptide derivative, MDP-L-alanyl-cholesterol (MTP-CHOL). J. Biol. Resp. Mod. 1985, 4, 464-474.
22. Phillips, N. C.; Rioux, J.; Tsao, M. S. Activation of murine Küpffer cell tumoricidal activity by liposomes containing lipophilic muramyl dipeptide. Hepatology 1988, 8, 1046-1050.
23. Seyler, I.; Morin, C.; Barratt, G.; Appel, M.; Devissaguet, J.-Ph.; Puisieux, F. Induction of macrophage NO-synthase activity by an immunomodulator entrapped within polymeric nanocapsules. Eur. J. Pharm. Biopharm. 1995, 41, 49-54.
24. Sponton, E.; Drouin, D.; Delattre, J.; Puisieux, F.; Tenu, J. P.; Yapo, A.; Barratt, G.; Petit, J. F. Design of sterile muramyldipeptide-containing oligolamellar liposomes suitable for i.v. injection. Effect of liposome size and lipid composition on their ability to render peritoneal macrophages antitumoral. Int. J. Pharmaceut. 1985, 23, 299-313.
25. Tenu, J.-P.; Roche, A.-C.; Yapo, A.; Kieda, C.; Monsigny, M.; Petit, J. F. Absence of surface receptors for muramylpeptides in mouse peritoneal macrophages. Biol. Cell 1982, 44, 157-164.
26. 125I-labelled aryl-azide derivatives of muramyldipeptide. Int. J. Immunopharmacol. 1989, 11, 653-661.
27. Wiley, G. A.; Hershowitz, R. L.; Rein, B. M.; Chung, B. C. Studies in organophosphorus chemistry. I. Conversion of alcohols and phenols to halides by tertiary phosphine dihalides. J. Am. Chem. Soc. 1964, 86, 964-965.
28. 2pm-D-Ala-D-Ala in mice. Evaluation of their ability to increase non specific resistance to Klebsiella infection. Int. J. Immunopharmacol. 1982, 4, 143-149.
29. Yu, W. P.; Barratt, G. M.; Devissaguet, J. P.; Puisieux, F. Antimetastatic activity in-vivo of MDP-L-alanyl-cholesterol (MTP-CHOL) entrapped in nanocapsules. Int. J. Immunopharmacol. 1991, 13, 167-173.
30. Seyler, I. Unpublished results.